Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Adenocarcinoma of Lung 2Unspecified Childhood Solid Tumor, Protocol Specific 1Ovarian Neoplasms 1Limited Stage Small Cell Lung Cancer 1Carcinoma, Ovarian Epithelial 1Alveolar Childhood Rhabdomyosarcoma 1

Interventions

Carboplatin 43Paclitaxel 33Specimen Handling 15Taxes 14Cyclophosphamide 14Magnetic Resonance Spectroscopy 12Gemcitabine 12Biopsy 12Bevacizumab 12aldesleukin 11Immunoglobulin G 11Disulfides 11veliparib 9Topotecan 9Doxorubicin 9Cisplatin 9Docetaxel 8fludarabine 7olaparib 6liposomal doxorubicin 6Oxaliplatin 6Chemotherapy, Adjuvant 5talazoparib 4sargramostim 4pembrolizumab 4cediranib 4Nivolumab 4Fluorouracil 4Drug Therapy 4sapanisertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Ovarian Neoplasms × Tirapazamine × Clear all
NCT00020696 2012-01-10

Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡